Biopharma Daily Stock Updates - 01/15/21

$XBI $151.73 (-1.11%) 📉


PIPELINE:

$AVEO (-0.37%) - AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

http://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-results-phase-1b-portion-deductive-study


$FPRX (-10.90%) - Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

https://investor.fiveprime.com/news-releases/news-release-details/phase-2-fight-trial-results-presented-asco-gi-validate


$PBYI (-2.00%) - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI

https://investor.pumabiotechnology.com/news-releases/news-details/2021/Puma-Biotechnology-Presents-Interim-Results-from-the-Biliary-Tract-Cancers-Cohort-of-the-Phase-II-SUMMIT-Basket-Trial-of-Neratinib-at-ASCO-GI/default.aspx


$VBIV (+0.16%) - VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine

https://www.vbivaccines.com/wire/results-of-phase-4-hepatitis-b-study/


$CRDF (-31.22%) - Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

https://cardiffoncology.investorroom.com/2021-01-15-Cardiff-Oncology-Presents-Data-that-Continues-to-Demonstrate-the-Clinical-Benefit-of-Onvansertib-in-KRAS-Mutated-mCRC-and-Initial-Findings-from-its-Expanded-Access-Program


$ZYME (-1.35%) - Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

https://ir.zymeworks.com/News-Releases/news-details/2021/Zanidatamab-Data-Highlight-Durable-Antitumor-Activity-in-HER2Expressing-Biliary-Tract-and-Gastroesophageal-Cancers-at-ASCO-Gastrointestinal-Cancers-Symposium/default.aspx



0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE